When limited to 30 adenocarcinoma cases, the frequency of the nine driver mutations detected was 56.7% (n = 17) with the AmoyDx PLC panel and 60% (n = 18) with ODxTT‐M. This evidence concerns the gene HSPG2 and adenocarcinoma.